Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model

Autor: Kaname Yamamoto, Masamichi Sugimoto, Mitsue Kurasawa, Keigo Yorozu, Nobuyuki Ishikura, Mieko Yanagisawa
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Cancer Research
genetic structures
Angiogenesis
medicine.medical_treatment
Apoptosis
Polyethylene Glycols
Mice
angiogenesis
chemistry.chemical_compound
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Tumor Cells
Cultured
bevacizumab beyond progression
Ovarian Neoplasms
Mice
Inbred BALB C
Neovascularization
Pathologic
Articles
General Medicine
Paclitaxel
030220 oncology & carcinogenesis
Clear cell carcinoma
Adenocarcinoma
Female
medicine.drug
medicine.medical_specialty
Bevacizumab
maintenance therapy
PEGylated liposomal doxorubicin
Mice
Nude
bevacizumab
03 medical and health sciences
Internal medicine
medicine
Animals
Humans
Cell Proliferation
Chemotherapy
business.industry
insulin-like growth factor binding protein-3
Cancer
medicine.disease
Xenograft Model Antitumor Assays
eye diseases
ovarian clear cell carcinoma
030104 developmental biology
chemistry
Doxorubicin
sense organs
Ovarian cancer
business
Adenocarcinoma
Clear Cell
Zdroj: Oncology Reports
ISSN: 1791-2431
1021-335X
DOI: 10.3892/or.2019.7211
Popis: Although bevacizumab maintenance following bevacizumab in combination with chemotherapy has demonstrated significant prolongation of progression-free survival in clinical studies in patients with ovarian cancer, the majority of the cancer cases in the study were of the serous histotype; therefore, data regarding clear cell carcinoma is limited. Furthermore, the efficacy of bevacizumab beyond progression has not yet been demonstrated in ovarian cancer. A xenograft model using the human ovarian clear cell carcinoma cell line RMG-I was used to investigate the antitumor effects and the mechanisms of bevacizumab in maintenance treatment and bevacizumab when administered beyond disease progression. In the RMG-I model, bevacizumab maintenance following bevacizumab in combination with paclitaxel exhibited increased tumor suppression, compared with its absence, and inhibited the increase of microvessel density (MVD) in tumors. Following disease progression during bevacizumab maintenance, continued bevacizumab treatment in combination with PEGylated liposomal doxorubicin as a secondary chemotherapeutic agent had increased efficacy, compared with PEGylated liposomal doxorubicin alone, and resulted in lower MVD accompanied with lower levels of insulin-like growth factor binding protein-3, which is reported to have angiogenic activity. Continuous suppression of angiogenesis by bevacizumab may contribute to the superior efficacy of bevacizumab maintenance and bevacizumab beyond progression in ovarian cancer.
Databáze: OpenAIRE
Externí odkaz: